Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 ...
A class of drugs designed to fight diabetes and weight loss can help with a host of other problems, but also carry some side ...
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
To corral costs, Keith is leading a new initiative at BCBSM called Blue Cross Accelerated that aims to cut $600 million in administrative costs.
Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...
About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...
Hosted on MSN5d
GLP-1 Drugs Cut Risk of Alzheimer's, NVO & LLY Shares RiseThe stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback